# Innoviva (INVA) — News

INVA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/inva/news

## Recent headlines

- [Innoviva Specialty Therapeutics in distribution, licensing pact](https://www.ainvest.com/news/innoviva-specialty-therapeutics-distribution-licensing-pact-2606) — AInvest Wire, Jun 16, 2026
- [Innoviva specialty therapeutics pact w/ Dr. Reddy’s on Xacduro](https://www.ainvest.com/news/innoviva-specialty-therapeutics-pact-dr-reddy-xacduro-2606) — AInvest Wire, Jun 16, 2026
  Innoviva Specialty Therapeutics has entered into a licensing agreement with Dr. Reddy’s Laboratories for the commercialization of XACDURO® (sulbactam/durlobactam for injection) in select international markets. XACDURO, approved by the U.S. Food and Drug Administration (FDA) in May 2023, is first…
- [Innoviva - to receive upfront, milestone payments and tiered royalties under agreement](https://www.ainvest.com/news/innoviva-receive-upfront-milestone-payments-tiered-royalties-agreement-2606) — AInvest Wire, Jun 16, 2026
- Zai Lab, Innoviva gets China’s NMPA approval for xacduro — AInvest Wire, May 20, 2024
  Zai Lab, Innoviva gets China’s NMPA approval for xacduro Introduction: Zai Lab (NASDAQ: ZLAB) and Innoviva, Inc. (NASDAQ: INVA) have announced that they have received approval from China's National Medical Products Administration (NMPA) for Xacduro (saxitoxumab). This is a significant milestone for…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).